Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]

PMID:
30858549
2.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961. [Epub ahead of print]

PMID:
30658992
3.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM.

Am J Hematol. 2019 Apr;94(4):408-416. doi: 10.1002/ajh.25394. Epub 2019 Jan 17.

PMID:
30623490
4.

Grading cardiac response in AL amyloidosis: implications for relapse and survival.

Eckhert E, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, O'Shaughnessy M, Liedtke M.

Br J Haematol. 2018 Dec 19. doi: 10.1111/bjh.15717. [Epub ahead of print] No abstract available.

PMID:
30569572
5.

Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.

Gong CL, Studdert AL, Liedtke M.

Am J Hematol. 2019 Mar;94(3):E68-E70. doi: 10.1002/ajh.25372. Epub 2018 Dec 18. No abstract available.

PMID:
30536952
6.

Antibody-based therapies in patients with acute lymphoblastic leukemia.

Dinner S, Liedtke M.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):9-15. doi: 10.1182/asheducation-2018.1.9. Review.

PMID:
30504286
7.

Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Yurkiewicz IR, Muffly L, Liedtke M.

Drug Des Devel Ther. 2018 Jul 24;12:2293-2300. doi: 10.2147/DDDT.S150317. eCollection 2018. Review.

8.

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.

Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.

9.

Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.

Yurkiewicz IR, Simon P, Liedtke M, Dahl G, Dunn T.

J Adolesc Young Adult Oncol. 2018 Oct;7(5):579-583. doi: 10.1089/jayao.2018.0022. Epub 2018 Jun 20.

PMID:
29924668
10.

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.

Dinner S, Dunn TJ, Price E, Coutré SE, Gotlib J, Berube C, Kaufman GP, Medeiros BC, Liedtke M.

Int J Hematol. 2018 Sep;108(3):267-273. doi: 10.1007/s12185-018-2468-5. Epub 2018 May 25.

PMID:
29802551
11.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

PMID:
29407182
12.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

PMID:
29381191
13.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

14.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
15.

Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).

Tuzovic M, Kobayashi Y, Wheeler M, Barrett C, Liedtke M, Lafayette R, Schrier S, Haddad F, Witteles R.

Am J Cardiol. 2017 Oct 15;120(8):1381-1386. doi: 10.1016/j.amjcard.2017.07.025. Epub 2017 Jul 25.

PMID:
28844519
16.

Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

Hansmann L, Han A, Penter L, Liedtke M, Davis MM.

Cancer Immunol Res. 2017 Sep;5(9):744-754. doi: 10.1158/2326-6066.CIR-17-0012. Epub 2017 Aug 2.

17.

Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.

Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA, Mukherjee S, Gerds AT, Hamilton BK, Carraway HE, Advani AS.

Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11.

PMID:
28693363
18.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M.

Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.

19.

Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016.

Maurer M, Lousada I, Hanna M, Ruberg F, Mohty D, Dispenzieri A, Liedtke M, Paulson I, Vest J, Grogan M.

Amyloid. 2017 Mar;24(sup1):165-166. doi: 10.1080/13506129.2017.1286582. No abstract available.

PMID:
28434366
20.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
21.

Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response.

Jiang D, Lynch C, Medeiros BC, Liedtke M, Bam R, Tam AB, Yang Z, Alagappan M, Abidi P, Le QT, Giaccia AJ, Denko NC, Niwa M, Koong AC.

Sci Rep. 2016 Sep 16;6:33353. doi: 10.1038/srep33353.

22.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS.

N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.

23.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

24.

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Dunn TJ, Dinner S, Price E, Coutré SE, Gotlib J, Hao Y, Berube C, Medeiros BC, Liedtke M.

Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4.

PMID:
27040320
25.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

26.

Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.

Leatham HW, Novoa R, Liedtke M, Kwong BY.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):e1-5. doi: 10.1016/j.clml.2015.11.007. Epub 2015 Nov 22. Review. No abstract available.

PMID:
26708980
27.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

28.

CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Iwasaki M, Liedtke M, Gentles AJ, Cleary ML.

Cell Stem Cell. 2015 Oct 1;17(4):412-21. doi: 10.1016/j.stem.2015.08.008. Epub 2015 Sep 18.

29.

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.

Narayan R, Garcia JS, Percival ME, Berube C, Coutre S, Gotlib J, Greenberg P, Liedtke M, Hewitt R, Regan K, Williamson C, Doykan C, Cardone MH, McMillan A, Medeiros BC.

Leuk Lymphoma. 2016;57(3):609-15. doi: 10.3109/10428194.2015.1091930. Epub 2015 Oct 13.

PMID:
26374199
30.

Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.

Hansmann L, Blum L, Ju CH, Liedtke M, Robinson WH, Davis MM.

Cancer Immunol Res. 2015 Jun;3(6):650-60. doi: 10.1158/2326-6066.CIR-14-0236-T. Epub 2015 Feb 20.

31.

Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.

Liedtke M, Dunn T, Dinner S, Coutré SE, Berube C, Gotlib J, Patel S, Medeiros B.

Leuk Res. 2014 Dec;38(12):1441-5. doi: 10.1016/j.leukres.2014.09.018. Epub 2014 Oct 6.

PMID:
25449689
32.

Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression.

Ohgami RS, Sendamarai AK, Atwater SK, Liedtke M, Fleming MD, Natkunam Y, Warnke RA.

Am J Surg Pathol. 2014 Sep;38(9):1298-304. doi: 10.1097/PAS.0000000000000197.

PMID:
24618611
33.

Effects of serum and plasma matrices on multiplex immunoassays.

Rosenberg-Hasson Y, Hansmann L, Liedtke M, Herschmann I, Maecker HT.

Immunol Res. 2014 May;58(2-3):224-33. doi: 10.1007/s12026-014-8491-6.

34.

AL amyloidosis or multiple myeloma? An important distinction--response to Falk.

Dinner S, Liedtke M.

Br J Haematol. 2014 Mar;164(5):749-50. doi: 10.1111/bjh.12672. Epub 2013 Dec 17. No abstract available.

PMID:
24344936
35.

Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.

Dinner S, Lee D, Liedtke M.

Leuk Lymphoma. 2014 Aug;55(8):1715-24. doi: 10.3109/10428194.2013.856428. Epub 2014 Apr 25. Review.

PMID:
24251864
36.

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.

Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, Schrier SL, Witteles RM.

Heart Rhythm. 2014 Jan;11(1):158-62. doi: 10.1016/j.hrthm.2013.10.026. Epub 2013 Oct 10. No abstract available.

PMID:
24121001
37.

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.

Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, Rappley I, Vogel H, Liedtke M, Witteles RM, Powers ET, Reixach N, Chan WK, Wilson IA, Kelly JW, Graef IA, Alhamadsheh MM.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9992-7. doi: 10.1073/pnas.1300761110. Epub 2013 May 28.

38.

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.

Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, Schrier SL, Liedtke M.

Haematologica. 2013 Oct;98(10):1593-9. doi: 10.3324/haematol.2013.084574. Epub 2013 May 28.

39.

The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.

Dinner S, Witteles W, Witteles R, Lam A, Arai S, Lafayette R, George TI, Schrier SL, Liedtke M.

Br J Haematol. 2013 May;161(3):367-72. doi: 10.1111/bjh.12269. Epub 2013 Feb 23.

PMID:
23432783
40.

A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.

Patel S, Liedtke M, Ngo D, Medeiros BC.

Leuk Lymphoma. 2013 Oct;54(10):2231-5. doi: 10.3109/10428194.2013.772606. Epub 2013 Mar 8.

PMID:
23383599
41.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Pollyea DA, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS, Medeiros BC.

Haematologica. 2013 Apr;98(4):591-6. doi: 10.3324/haematol.2012.076414. Epub 2012 Dec 14.

42.

Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options.

Dunn T, Cho M, Medeiros B, Logan A, Ungewickell A, Liedtke M.

Hematology. 2012 Nov;17(6):325-8. doi: 10.1179/1607845412Y.0000000007. Review.

PMID:
23168071
43.

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.

Sun D, Elson P, Liedtke M, Medeiros BC, Earl M, Alizadeh A, Bates J, Sekeres MA, Coutre S, Kalaycio M, Sobecks R, Copelan E, Advani AS.

Am J Hematol. 2012 Oct;87(10):957-60. doi: 10.1002/ajh.23279. Epub 2012 Jun 22.

44.

More than a frog in the throat: a case series and review of localized laryngeal amyloidosis.

Stevenson R, Witteles R, Damrose E, Arai S, Lafayette RA, Schrier S, Afghahi A, Liedtke M.

Arch Otolaryngol Head Neck Surg. 2012 May;138(5):509-11. doi: 10.1001/archoto.2012.423. Review. No abstract available.

PMID:
22652951
45.

The transcription factor encyclopedia.

Yusuf D, Butland SL, Swanson MI, Bolotin E, Ticoll A, Cheung WA, Zhang XY, Dickman CT, Fulton DL, Lim JS, Schnabl JM, Ramos OH, Vasseur-Cognet M, de Leeuw CN, Simpson EM, Ryffel GU, Lam EW, Kist R, Wilson MS, Marco-Ferreres R, Brosens JJ, Beccari LL, Bovolenta P, Benayoun BA, Monteiro LJ, Schwenen HD, Grontved L, Wederell E, Mandrup S, Veitia RA, Chakravarthy H, Hoodless PA, Mancarelli MM, Torbett BE, Banham AH, Reddy SP, Cullum RL, Liedtke M, Tschan MP, Vaz M, Rizzino A, Zannini M, Frietze S, Farnham PJ, Eijkelenboom A, Brown PJ, Laperrière D, Leprince D, de Cristofaro T, Prince KL, Putker M, del Peso L, Camenisch G, Wenger RH, Mikula M, Rozendaal M, Mader S, Ostrowski J, Rhodes SJ, Van Rechem C, Boulay G, Olechnowicz SW, Breslin MB, Lan MS, Nanan KK, Wegner M, Hou J, Mullen RD, Colvin SC, Noy PJ, Webb CF, Witek ME, Ferrell S, Daniel JM, Park J, Waldman SA, Peet DJ, Taggart M, Jayaraman PS, Karrich JJ, Blom B, Vesuna F, O'Geen H, Sun Y, Gronostajski RM, Woodcroft MW, Hough MR, Chen E, Europe-Finner GN, Karolczak-Bayatti M, Bailey J, Hankinson O, Raman V, LeBrun DP, Biswal S, Harvey CJ, DeBruyne JP, Hogenesch JB, Hevner RF, Héligon C, Luo XM, Blank MC, Millen KJ, Sharlin DS, Forrest D, Dahlman-Wright K, Zhao C, Mishima Y, Sinha S, Chakrabarti R, Portales-Casamar E, Sladek FM, Bradley PH, Wasserman WW.

Genome Biol. 2012;13(3):R24. doi: 10.1186/gb-2012-13-3-r24.

46.

Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies.

Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM.

J Heart Lung Transplant. 2012 Mar;31(3):325-31. doi: 10.1016/j.healun.2011.09.010. Epub 2011 Nov 3.

PMID:
22051505
47.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, Coutre SE.

Haematologica. 2012 Jan;97(1):30-7. doi: 10.3324/haematol.2011.045997. Epub 2011 Oct 11.

48.

Plasma cell leukemia: concepts and management.

Liedtke M, Medeiros BC.

Expert Rev Hematol. 2010 Oct;3(5):543-9. doi: 10.1586/ehm.10.52. Review.

PMID:
21083471
49.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.

Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC.

Am J Hematol. 2010 Nov;85(11):877-81. doi: 10.1002/ajh.21857.

50.

Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6.

Liedtke M, Ayton PM, Somervaille TC, Smith KS, Cleary ML.

Blood. 2010 Jul 8;116(1):63-70. doi: 10.1182/blood-2009-09-243386. Epub 2010 Apr 15.

Supplemental Content

Loading ...
Support Center